Search
Nateglinide
go.drugbank.com/drugs/DB00731ApprovedOne minor metabolite, the isoprene, has the same potency as its parent compound. … The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents.
Remestemcel-L
go.drugbank.com/drugs/DB13973ApprovedInvestigationalWithdrawnIt was approved for use in Canada in May 2012 as Prochymal for the management of refractory acute Graft versus Host Disease (aGvHD) in children who are unresponsive to systemic steroid therapies, with … with first-line therapies, putting them in a risk for poor outcomes and creating a significant clinical challenge [A31818].
Calcium polycarbophil
go.drugbank.com/drugs/DB14684ApprovedLess gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali. … Polycarbophil is used to treat constipation. This drug may also be used to help relieve the symptoms of irritable bowel syndrome or diarrhea.
Categories: Drugs for Constipation, Compounds used in a research, industrial, or household settingCannabidiol
go.drugbank.com/drugs/DB09061ApprovedInvestigationalanalgesic treatment for moderate to severe pain in adult patients with advanced cancer [L886]. … It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: leafPro CBDmed Oil T-FS QD 5%, leafPro CBDmed Oil T-FS QD 20%Dextropropoxyphene
go.drugbank.com/drugs/DB00647ApprovedIllicitWithdrawnThe drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. … Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeAsunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawnIt has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. … [A32528] It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.[L1113]
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseReslizumab
go.drugbank.com/drugs/DB06602ApprovedInvestigationalBy targeting the IL-5 and disrupting its signalling pathways, reslizumab aims to inhibit eosinophil maturation and promote programmed cell death [A31578]. … In four double-blind, randomized, placebo‑controlled trials in patients with severe asthma on currently available therapies, patients receiving reslizumab had fewer asthma attacks, and a longer time to
Categories: Drugs for Obstructive Airway DiseasesSermorelin
go.drugbank.com/drugs/DB00010ApprovedWithdrawnSermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing … hormone (GHRH or GRF) consisting of 44 amino acid residues
Categories: Tests for Pituitary FunctionLamotrigine
go.drugbank.com/drugs/DB00555ApprovedInvestigationalLamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 countries. … While it is indicated for epilepsy and bipolar disorders, there is evidence that lamotrigine could have some clinical efficacy in certain neuropathic pain states.[A849,A850]
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesProducts: LAMOTRIGINA POR 200 MGBeremagene geperpavec
go.drugbank.com/drugs/DB17831ApprovedInvestigationalDeveloped by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). … [L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component of the anchoring fibrils for dermal–epidermal cohesion.
Categories: Preparations for Treatment of Wounds and Ulcers